-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
MDNA Life Sciences has announced its Particulate Prostate Test (MPT), the world's most accurate blood test to determine whether a man has prostate cancer that requires treatment, and now MDNA partner Aspire Pharma is on the market in the UK for clinical use.
Private medical clinics provide secret tests for self-funded patients, pass private clinic tests, and submit test reports from HMR Laboratories in London.
It works by using the unique characteristics of mitochondrial DNA mutations as biomarkers, which may mean the clinically obvious presence of prostate cancer. A clinical study conducted in collaboration with the University of Cambridge showed that MPT biomarkers had a negative prediction of more than 99 per cent, meaning that men with negative MPT results could safely delay or avoid further diagnostic tests because they were highly unlikely to have clinically significant prostate cancer.
MPT is also 92% sensitive, which means that men with positive results can have immediate medical intervention.
Dr Nikhil Chopra, Education Secretary of the Primary Care Urology Association, explained: "Prostate cancer has so far been difficult to diagnose, and current diagnostic methods are limited and create uncertainty. A simple blood-based test that provides more accurate and accurate information about deciding to have a biopsy is a welcome addition and may somehow reduce the problem we face in diagnosing low-level malignancies.
In the patient types targeted in this trial, those with elevated PSAs but no clear evidence of high-level diseases can positively influence how we diagnose and differentiate people in need of treatment from prostate cancer patients who do not require treatment.
Prostate cancer detection currently relies heavily on measuring prostate-specific antigen (PSA) levels, which can give well-known high false positive results. Only 25 per cent of men who found PSA levels to rise had prostate cancer, leading to millions of men being wrongly referred for prostate biopsies. MPT can help reduce the number of prostate biopsies by up to 30%. (Compiled by this web)
